🚀 VC round data is live in beta, check it out!
Spago Nanomedical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Spago Nanomedical and similar public comparables like TME Pharma, Pila Pharma, Addex Therapeutics, Bolt Biotherapeutics and more.
Spago Nanomedical Overview
About Spago Nanomedical
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
Founded
2007
HQ
Employees
13
Website
Sectors
Financials (LTM)
EV
$5M
Spago Nanomedical Financials
Spago Nanomedical reported last 12-month revenue of — and negative EBITDA of ($3M).
In the same LTM period, Spago Nanomedical generated — in gross profit, ($3M) in EBITDA losses, and had net loss of ($3M).
Revenue (LTM)
Spago Nanomedical P&L
In the most recent fiscal year, Spago Nanomedical reported revenue of $48K and EBITDA of ($3M).
Spago Nanomedical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $48K | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($1M) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (2527%) | XXX | XXX | XXX |
| EBITDA | ($3M) | XXX | ($3M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (6127%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (6166%) | XXX | XXX | XXX |
| Net Profit | ($3M) | XXX | ($3M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (6076%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Spago Nanomedical Stock Performance
Spago Nanomedical has current market cap of $9M, and enterprise value of $5M.
Market Cap Evolution
Spago Nanomedical's stock price is $0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5M | $9M | 0.3% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSpago Nanomedical Valuation Multiples
Spago Nanomedical trades at 112.3x EV/Revenue multiple, and (1.7x) EV/EBITDA.
EV / Revenue (LTM)
Spago Nanomedical Financial Valuation Multiples
As of April 19, 2026, Spago Nanomedical has market cap of $9M and EV of $5M.
Equity research analysts estimate Spago Nanomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Spago Nanomedical has a P/E ratio of (2.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9M | XXX | $9M | XXX | XXX | XXX |
| EV (current) | $5M | XXX | $5M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 112.3x | XXX | XXX | XXX |
| EV/EBITDA | (1.7x) | XXX | (1.8x) | XXX | XXX | XXX |
| EV/EBIT | (1.7x) | XXX | (1.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (4.4x) | XXX | XXX | XXX |
| P/E | (2.8x) | XXX | (3.0x) | XXX | XXX | XXX |
| EV/FCF | (1.8x) | XXX | (1.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Spago Nanomedical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Spago Nanomedical Margins & Growth Rates
Spago Nanomedical's revenue in the last fiscal year declined by (100%).
Spago Nanomedical's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.1M for the same period.
Spago Nanomedical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (6127%) | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | 16% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 3638% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Spago Nanomedical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Spago Nanomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| TME Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pila Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Addex Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Bolt Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| OncoZenge | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Spago Nanomedical M&A Activity
Spago Nanomedical acquired XXX companies to date.
Last acquisition by Spago Nanomedical was on XXXXXXXX, XXXXX. Spago Nanomedical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Spago Nanomedical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSpago Nanomedical Investment Activity
Spago Nanomedical invested in XXX companies to date.
Spago Nanomedical made its latest investment on XXXXXXXX, XXXXX. Spago Nanomedical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Spago Nanomedical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Spago Nanomedical
| When was Spago Nanomedical founded? | Spago Nanomedical was founded in 2007. |
| Where is Spago Nanomedical headquartered? | Spago Nanomedical is headquartered in Sweden. |
| How many employees does Spago Nanomedical have? | As of today, Spago Nanomedical has over 13 employees. |
| Is Spago Nanomedical publicly listed? | Yes, Spago Nanomedical is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Spago Nanomedical? | Spago Nanomedical trades under SPAGO ticker. |
| When did Spago Nanomedical go public? | Spago Nanomedical went public in 2012. |
| Who are competitors of Spago Nanomedical? | Spago Nanomedical main competitors are TME Pharma, Pila Pharma, Addex Therapeutics, Bolt Biotherapeutics. |
| What is the current market cap of Spago Nanomedical? | Spago Nanomedical's current market cap is $9M. |
| What is the current revenue growth of Spago Nanomedical? | Spago Nanomedical revenue growth (vs. last FY) is (100%). |
| What is the current EV/Revenue multiple of Spago Nanomedical? | Current revenue multiple of Spago Nanomedical is 112.3x. |
| Is Spago Nanomedical profitable? | No, Spago Nanomedical is not profitable. |
| What is the current EBITDA of Spago Nanomedical? | Spago Nanomedical has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Spago Nanomedical? | Current EBITDA multiple of Spago Nanomedical is (1.7x). |
| What is the current FCF of Spago Nanomedical? | Spago Nanomedical's last 12 months FCF is ($3M). |
| What is the current EV/FCF multiple of Spago Nanomedical? | Current FCF multiple of Spago Nanomedical is (1.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.